ATR-258

Phase 2Small molecule

AAtrogi AB

ATR-258 is one of 3 small molecule programs targeting Overweight and Obesity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Overweight and ObesityActive, not recruiting

Overweight and ObesityPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Overweight and Obesity

#DrugCompanyPhaseTrials

ATR-258

AAtrogi AB

Phase 2

1 2

LAE102 IV

LLaekna Limited

Phase 1

1 3

AZD9550

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Overweight and Obesity

NCT07421024

Clinical

Trials by Indication[1]

Trial2 trials

The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers

Completed·AAtrogi AB·Phase 1·NCT06432673·21 enrolled

First-in-human Single and Multiple Dose Trial of ATR-258

Completed·AAtrogi AB·Phase 1·NCT05409924·71 enrolled

Overweight and Obesity1 trial

G Protein-Coupled Receptor Kinase (GRK)-Biased Signaling Via β2-Adrenergic Receptors and Downstream Activation and Its Role for Protein Synthesis-Regulating Kinases, Function and Receptor Desensitization in Human Skeletal Muscle

Active, not recruiting·MMorten Hostrup, PhD·Phase 2·NCT07421024·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ATR-258. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATR-258 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATR-258. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atrogi AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAtrogi AB

ATR-258

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Trial2 trials

Overweight and Obesity1 trial

References

Drug Info

Quick Facts

Related News